The potential of three-dimensional printing for pediatric oral solid dosage forms
Acta Pharmaceutica · 2024
DOI: 10.2478/acph-2024-0012 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Pharmaceutica, 2024. Verfasst von Klemen Kreft und 2 weiteren Autor:innen. Beteiligte Einrichtung: 1Lek Pharmaceuticals d.d., a Sandoz Company, 1000 Ljubljana, Slovenia. Hauptthemen laut MEDLINE: Printing, Three-Dimensional, Tablets, Drug Compounding, Technology, Pharmaceutical. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Pediatric patients often require individualized dosing of medicine due to their unique pharmacokinetic and developmental characteristics. Current methods for tailoring the dose of pediatric medications, such as tablet splitting or compounding liquid formulations, have limitations in terms of dosing accuracy and palatability. This paper explores the potential of 3D printing as a solution to address the challenges and provide tailored doses of medication for each pediatric patient. The technological overview of 3D printing is discussed, highlighting various 3D printing technologies and their suitability for pharmaceutical applications. Several individualization options with the potential to improve adherence are discussed, such as individualized dosage, custom release kinetics, tablet shape, and palatability. To integrate the preparation of 3D printed medication at the point of care, a decentralized manufacturing model is proposed. In this setup, pharmaceutical companies would routinely provide materials and instructions for 3D printing, while specialized compounding centers or hospital pharmacies perform the printing of medication. In addition, clinical opportunities of 3D printing for dose-finding trials are emphasized. On the other hand, current challenges in adequate dosing, regulatory compliance, adherence to quality standards, and maintenance of intellectual property need to be addressed for 3D printing to close the gap in personalized oral medication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1Lek Pharmaceuticals d.d., a Sandoz Company, 1000 Ljubljana, Slovenia.
- 2Novartis Pharma AG, 4002 Basel Switzerland.
ORCID-Profile: Klemen Kreft
Zitieren
APA
Kreft, K., Fanous, M., & Möckel, V. (2024). The potential of three-dimensional printing for pediatric oral solid dosage forms. Acta Pharmaceutica. https://doi.org/10.2478/acph-2024-0012
Vancouver
Kreft K, Fanous M, Möckel V. The potential of three-dimensional printing for pediatric oral solid dosage forms. Acta Pharmaceutica. 2024. doi:10.2478/acph-2024-0012
BibTeX
@article{Kreft2024,
author = {Kreft, Klemen and Fanous, Marina and Möckel, Volker},
title = {The potential of three-dimensional printing for pediatric oral solid dosage forms},
journal = {Acta Pharmaceutica},
year = {2024},
doi = {10.2478/acph-2024-0012}
}
EUVIMED